A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Non-Small Cell Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT03273790

CA209-9CR

Details and patient eligibility

About

A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan

Enrollment: 939 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previously treated advanced/metastatic NSCLC patients treated with nivolumab at least once from 01-Apr-2016 through 31-Dec-2016

Exclusion criteria

Patients who meets the inclusion criteria will be included in the analysis to describe real-world clinical usage of nivolumab. However, patients treated with nivolumab falling in following criteria will be excluded for analysis for the other primary endpoint; overall effectiveness:

• History of participation in any clinical trials prior- or post-nivolumab treatment
• Patients who are a part of a Post-marketing surveillance study

Other protocol defined inclusion/exclusion criteria could apply

Trial design

939 participants in 1 patient group

NSCLC patients

Description:

Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016